An interventional study of Bacillus coagulans group and Control group in Constipation - Functional, sponsored by Pusan National University Yangsan Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Constipation with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Constipation · Korea, Republic of.
Among the 23 studies in Constipation with a site in Korea, Republic of, this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 with no phase, and was the 18th registered.
1,048 studies on the registry are indexed under Constipation; 163 are open to participants now.
Browse Constipation studies →2 of the 23 studies in Constipation with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–80
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19–63 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 75 across 889 interventional studies indexed under Constipation.
Median enrollment 80 across the 20 interventional studies, 461 across the 3 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 23 have an industry lead sponsor. The 10 most frequent:
Pusan National University Yangsan Hospital is the lead sponsor of 108 studies on the registry; 27 are open to participants now.
Pusan National University Yangsan Hospital has 2 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
1 of the studies in Constipation with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07923279Seoul National University HospitalEffects of a Prebiotic-Probiotic Combination on Constipation Symptoms and Quality of Life | 2027-01-15 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Constipation with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Bacillus coagulans on various symptoms and fecal microbial diversity in adults with with functional constipation for 12 weeks.
A previous study has indicated that Bacillus coagulans provided control of abdominal pain, less discomfort during defecation, and a more normalized defecation style, especially in adults with with functional constipation. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Bacillus coagulans various symptoms and fecal microbial diversity in adults with with functional constipation for 8 weeks; the safety of the compound are also evaluated. The Investigators examine constipation visual analogue scale, Bristol Stool Form Scale type 3 \& 4 ratio, visual analogue scale for irritable bowel syndrome (VAS-IBS) questionnaire score, IBS-symptom severity scale, IBS quality-of-life questionnaire score, fecal microbial diversity at baseline, as well as after 8 weeks of intervention. Eighty adults were administered either 400 mg of Bacillus coagulans or a placebo each day for 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- function constipation by Romes criteria IV
Exclusion Criteria:
This group takes Bacillus coagulans for 12 weeks.
Dietary Supplement: Bacillus coagulans group
This group takes placebo for 12 weeks.
Dietary Supplement: Control group
Bacillus coagulans 400 mg/day for 12 weeks
Placebo 400 mg/day for 12 weeks
constipation visual analogue scale
using visual analogue scale (100 mm). The minimum value was 0 mm and the maximum value was 100 mm, and higher scores mean a worse outcome.
Time frame: 8 weeks
Bristol Stool Form Scale (BSFS) type 1 & 2 ratio (%)
using Bristol Stool Form Scale. The minimum value was 0% and the maximum value was 100%, and higher scores mean a better outcome.
Time frame: 8 weeks
visual analogue scale for irritable bowel syndrome
using visual analogue scale (100 mm). The minimum value was 0 mm and the maximum value was 100 mm, and higher scores mean a better outcome.
Time frame: 8 weeks
irritable bowel syndrome-symptom severity scale
using IBS-Symptom Severity Scale questionnaire. The minimum value was 0 score and the maximum value was 500 score and higher scores mean a worse outcome.
Time frame: 8 weeks
irritable bowel syndrome-quality-of-life
using IBS-QOL questionnaire. The minimum value was 0 score and the maximum value was 5 score and higher scores mean a better outcome.
Time frame: 8 weeks
fecal microbial diversity
using gut microbiome analysis
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Feb 2022, 7 months.
Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 7 months is below that.
Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Heyndrickxia coagulans
Pusan National University Yangsan Hospital →